×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
OTCMKTS:SNPHY

Santen Pharmaceutical Stock Forecast, Price & News

$7.85
+0.04 (+0.51%)
(As of 07/1/2022 03:56 PM ET)
Add
Compare
Today's Range
$7.67
$7.90
50-Day Range
$7.22
$8.79
52-Week Range
$7.06
$15.70
Volume
39,792 shs
Average Volume
113,149 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Santen Pharmaceutical Stock Forecast (MarketRank)

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.56 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive SNPHY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

SNPHY Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers-General
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SNPHY
Fax
N/A
Employees
4,229
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A














Santen Pharmaceutical Frequently Asked Questions

Should I buy or sell Santen Pharmaceutical stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Santen Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Santen Pharmaceutical stock.
View analyst ratings for Santen Pharmaceutical
or view top-rated stocks.

How has Santen Pharmaceutical's stock performed in 2022?

Santen Pharmaceutical's stock was trading at $12.18 at the beginning of 2022. Since then, SNPHY shares have decreased by 35.6% and is now trading at $7.85.
View the best growth stocks for 2022 here
.

Are investors shorting Santen Pharmaceutical?

Santen Pharmaceutical saw a decline in short interest in June. As of June 15th, there was short interest totaling 400 shares, a decline of 90.9% from the May 31st total of 4,400 shares. Based on an average trading volume of 313,600 shares, the days-to-cover ratio is presently 0.0 days.
View Santen Pharmaceutical's Short Interest
.

Who are Santen Pharmaceutical's key executives?

Santen Pharmaceutical's management team includes the following people:
  • Mr. Shigeo Taniuchi, Pres, CEO & Representative Director (Age 49, Pay $779.23k)
  • Mr. Kazuo Koshiji, Chief Financial Officer & Chief Risk Officer
  • Mr. Minori Hara, Chief Digital & Information Officer
  • Ms. Kaori Itagaki, Gen. Mang. of Investor Relations Group
  • Ms. Mika Masunari, Gen. Counsel & Chief Compliance Officer
  • Ms. Nobuko Kato, Chief Communications Officer
  • Mr. Satoshi Suzuki, Sr. Corp. Officer & Head of Corp. Devel. Division
  • Mr. Shinichi Teramachi, Corp. Officer, Head of Sales Department & Japan Sales and Marketing Division
  • Mr. Ippei Kurihara, Corp. Officer, Head of Marketing Department & Japan Sales and Marketing Division
  • Mr. Tomo Yashiki, Corp. Officer & Head of HR Division

Who are some of Santen Pharmaceutical's key competitors?

What is Santen Pharmaceutical's stock symbol?

Santen Pharmaceutical trades on the OTCMKTS under the ticker symbol "SNPHY."

How do I buy shares of Santen Pharmaceutical?

Shares of SNPHY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Santen Pharmaceutical's stock price today?

One share of SNPHY stock can currently be purchased for approximately $7.85.

How many employees does Santen Pharmaceutical have?

Santen Pharmaceutical employs 4,229 workers across the globe.

How can I contact Santen Pharmaceutical?

Santen Pharmaceutical's mailing address is Kita-ku, Osaka Shi, Osaka Fu 530-8552. The official website for Santen Pharmaceutical is www.santen.com. The company can be reached via phone at (167) 664-8621.

This page (OTCMKTS:SNPHY) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.